Publications

• Lellahi SM, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, Kalland KH. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front Immunol. 2023 Jan 12;13:1058963. doi: 10.3389/fimmu.2022.1058963. PMID: 36713392; PMCID: PMC9880532
• Völker T, Mazzonetto M, Slaattelid R, Strand R. Translating tools and indicators in territorial RRI. Front Res Metr Anal. 2023 Jan 9;7:1038970. doi: 10.3389/frma.2022.1038970. PMID:36700150; PMCID: PMC9868598.
• Farndale R, Sonnenberg A, DiPersio CM, Eble JA, Heino J, Gullberg D. What does it take to be a collagen receptor? Matrix Biol. 2023 Jan;115:128-132. doi: 10.1016/j.matbio.2022.12.004. Epub 2022 Dec 24. PMID: 36574820.
• Fasmer KE, Gulati A, Dybvik JA, Wagner-Larsen KS, Lura N, Salvesen Ø, Forsse D, Trovik J, Pijnenborg JMA, Krakstad C, Haldorsen IS. Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer-time to revisit current imaging guidelines? Eur Radiol. 2023 Jan;33(1):221-232. doi: 10.1007/s00330-022-08949-3. Epub 2022 Jun 28. PMID: 35763096; PMCID: PMC9755079.
• Vrede SW, Kasius J, Bulten J, … and Pijnenborg JMA (incl. Amant F). Relevance of Molecular Profiling in Patients with Low-Grade Endometrial Cancer. JAMA Netw Open. 2022 Dec 1;5(12):e2247372. doi: 10.1001/jamanetworkopen.2022.47372. PMID: 36525269.
• Sui L, Wang S, Ganguly D, El Rayes TP, Askeland C, Børretzen A, Sim D, Halvorsen OJ, Knutsvik G, Arnes J, Aziz S, Haukaas S, Foulkes WD, Bielenberg DR, Ziemys A, Mittal V, Brekken RA, Akslen LA, Watnick RS. PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. Nat Commun. 2022 Dec 27;13(1):7959. doi: 10.1038/s41467-022-35649-9. PMID:36575174; PMCID: PMC9794699.
• Rahman MA, Engelsen AST, Sarowar S, Bindesbøll C, Birkeland E, Goplen D, Lotsberg ML, Knappskog S, Simonsen A, Chekenya M. Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. Front Cell Dev Biol. 2022 Dec 22;10:1022191. doi: 10.3389/fcell.2022.1022191. PMID: 36619857; PMCID: PMC9814514.
• Barrett JE, Jones A, Evans I, … and Widschwendter M (incl. Bjørge L). The WID-EC test for the detection and risk prediction of endometrial cancer. Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34406. Epub ahead of print. PMID: 36533702
• Othman J, Meggendorfer M, Tiacci E, … and Falini B (incl. Andresen V, Gjertsen BT). Overlapping features of therapyrelated and de novoNPM1-mutated AML. Blood. 2022 Dec 12:blood.2022018108. doi: 10.1182/blood.2022018108. Epub ahead of print. PMID: 36508705.
• Berg HF, Engerud H, Myrvold M, Lien HE, Hjelmeland ME, Halle MK, Woie K, Hoivik EA, Haldorsen IS, Vintermyr O, Trovik J, Krakstad C. Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02063-3. Epub ahead of print. PMID: 36482191.
• Kang J, Cairns J. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy. BMC Cancer. 2022 Dec 5;22(1):1268. doi: 10.1186/s12885-022-10350-8. PMID: 36471259; PMCID: PMC9724266.
• Thurfjell V, Micke P, Yu H, Krupar R, Svensson MA, Brunnström H, Lamberg K, Moens LNJ, Strell C, Gulyas M, Helenius G, Yoshida A, Goldmann T, Mattsson JSM. Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas. Transl Lung Cancer Res. 2022 Dec;11(12):2477-2494. doi:10.21037/tlcr-22-504. PMID: 36636421; PMCID: PMC9830269.
• Gaafar NM, Osman TA, Elsheikh M, Ahmed IA, Dongre H, Fromreide S, Suleiman AM, Johannessen AC, Nginamau ES, Costea DE. Epithelial PD-L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan. Clin Exp Dent Res. 2022 Dec;8(6):1467-1477. doi:10.1002/cre2.666. Epub 2022 Sep 30. PMID: 36177667; PMCID: PMC9760153.
• Zeltz C, Navab R, Heljasvaara R, Kusche-Gullberg M, Lu N, Tsao MS, Gullberg D. Integrin α11β1 in tumor fibrosis: more than just another cancer-associated fibroblast biomarker? J Cell Commun Signal. 2022 Dec;16(4):649-660. doi: 10.1007/s12079-022-00673-3. Epub 2022 Apr 4. PMID: 35378690; PMCID: PMC8978763.
• Herzog C, Marín F, Jones A, … and Widschwendter M (incl. Bjørge L). A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women with Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. J Clin Oncol. 2022 Nov 20;40(33):3828-3838. doi:10.1200/JCO.22.00266. Epub 2022 Aug 24. PMID: 36001862; PMCID: PMC9671754.
• Sofiyeva N, Krakstad C, Halle MK, O’Mara TA, Romundstad P, Hveem K, Vatten L, Lønning PE, Gansmo LB, Knappskog S. APOBEC3A/B deletion polymorphism and endometrial cancer risk. Cancer Med. 2022 Nov 16. doi: 10.1002/cam4.5448. Epub ahead of print. PMID: 36394079. 
• Lee SY, Robertson C, Diot A, Meuray V, Bourdon JC, Bissell MJ. Δ133p53 coordinates ECM-driven morphogenesis and gene expression in three-dimensional mammary epithelial acini. J Cell Sci. 2022 Nov 1;135(21):jcs259673. doi: 10.1242/jcs.259673. Epub 2022 Nov 4. PMID: 36239052; PMCID: PMC9687550.
• Lomakin A, Svedlund J, Strell C, … and Yates LR. Spatial genomics maps the structure, nature and evolution of cancer clones. Nature. 2022 Nov;611(7936):594-602. doi: 10.1038/s41586-022-05425-2. Epub 2022 Nov 9. PMID: 36352222; PMCID: PMC9668746.
• Ingebriktsen LM, Finne K, Akslen LA, Wik E. A novel agerelated gene expression signature associates with proliferation and disease progression in breast cancer. Br J Cancer. 2022 Nov;127(10):1865-1875. doi: 10.1038/s41416-022-01953-w. Epub 2022 Aug 23. PMID: 35995935; PMCID: PMC9643541. 
• Tettero JM, Al-Badri WKW, Ngai LL, … and Cloos J (incl. Gjertsen BT). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Front Oncol. 2022 Oct 10;12:999822. doi: 10.3389/fonc.2022.999822. PMID: 36300090; PMCID: PMC9589259. 
• Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Roder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Tasken KA. Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer. Eur Urol Open Sci. 2022 Oct 4;45:68-75. doi: 10.1016/j. euros.2022.09.002. eCollection 2022 Nov. PMID: 36353660. 
• Chakravarthy A, Reddin I, Henderson S, … and Fenton TR (incl. Halle MK, Krakstad C, Salvesen H). Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. Nat Commun. 2022 Oct 7;13(1):5818. doi: 10.1038/s41467-022-33544-x. PMID: 36207323; PMCID: PMC9547055.
• Steffens Reinhardt L, Zhang X, Groen K, Morten BC, De Iuliis GN, Braithwaite AW, Bourdon JC, Avery-Kiejda KA. Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage. Cell Death Dis. 2022 Oct 28;13(10):907. doi: 10.1038/s41419-022-05349-9. PMID: 36307393; PMCID: PMC9616954.
• Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment. ESMO Open. 2022 Oct;7(5):100588. doi: 10.1016/j.esmoop.2022.100588. Epub 2022 Sep 16. PMID: 36116420; PMCID: PMC9588897. 
• Sommerfelt H, Sandvik LF, Bachmann IM, Brekke RL, Svendsen HL, Guttormsen AB, Aziz S, Dillekås H, Straume O. Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. Acta Oncol.
  2022 Oct;61(10):1295-1299. doi: 10.1080/0284186X.2022.2119099. Epub 2022 Sep 8. PMID: 36073292. 
• Kang J, Cairns J. “Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England. Pharmacoecon Open. 2022 Sep 20. doi: 10.1007/s41669-022-00369-9. Epub ahead of print. PMID: 36123583.
• Huuhtanen J, Ilander M, Yadav B, … and Mustjoki S (incl. Gjertsen BT). IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J Clin Invest. 2022 Sep 1;132(17):e152585. doi:10.1172/JCI152585. PMID: 36047494; PMCID: PMC9433106. 
• Rodriguez-Tirado C, Entenberg D, Li J, Qian B-Z, Condeelis JS, Pollard JW. Interleukin 4 Controls the Pro-Tumoral Role of Macrophages in Mammary Cancer Pulmonary Metastasis in Mice. Cancers (Basel). 2022 Sep 5;14(17):4336. doi: 10.3390/
  cancers14174336. PMID: 36077870.
• Che H, Jatsenko T, Lenaerts L, … and Vermeesch JR (incl. Amant F). Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clin Chem. 2022 Sep 1;68(9):1164-1176. doi: 10.1093/clinchem/hvac095. PMID: 35769009.
• Wagner-Larsen KS, Lura N, Salvesen Ø, Halle MK, Forsse D, Trovik J, Smit N, Krakstad C, Haldorsen IS. Interobserver agreement and prognostic impact for MRI-based 2018 FIGO staging parameters in uterine cervical cancer. Eur Radiol. 2022 Sep;32(9):6444-6455. doi: 10.1007/s00330-022-08666-x. Epub 2022 Mar 24. PMID: 35332408; PMCID: PMC9381622.
• Martínez-Nieto GA, Teppo HR, Petrelius N, Izzi V, Devarajan R, Petäistö T, Liu H, Kim KS, Karppinen SM, Ruotsalainen H, Koivunen J, Mäki JM, Walker GC, Pihlajaniemi T, Gullberg D, Heljasvaara R. Upregulated integrin α11 in the stroma of cutaneous squamous cell carcinoma promotes skin carcinogenesis. Front Oncol. 2022 Aug 8;12:981009. doi: 10.3389/fonc.2022.981009. PMID:36003785; PMCID: PMC9393502.
• Erickson A, He M, Berglund E, … and Lundeberg J (incl. Mills IG). Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. 2022 Aug;608(7922):360-367. doi: 10.1038/s41586-022-05023-2. Epub 2022 Aug 10. PMID: 35948708.
• Van Nyen T, Planque M, van Wagensveld L, … and Amant F. Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. Nat Commun. 2022 Aug 5;13(1):4578. doi: 10.1038/s41467-022-32272-6. PMID: 35931688. 
• Krebs N, Klein L, Wegwitz F, Espinet E, Maurer HC, Tu M, Penz F, Küffer S, Xu X, Bohnenberger H, Cameron S, Brunner M, Neesse A, Kishore U, Hessmann E, Trumpp A, Ströbel P, Brekken RA, Ellenrieder V, Singh SK. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. JCI Insight. 2022 Aug 22;7(16):e154475. doi:10.1172/jci.insight.154475.PMID: 35993361. 
• Larrieu CM, Storevik S, Guyon J, Pagano Zottola AC, Bouchez CL, Derieppe MA, Tan TZ, Miletic H, Lorens J, Tronstad KJ, Daubon T, Røsland GV. Refining the Role of Pyruvate Dehydrogenase Kinases in Glioblastoma Development. Cancers (Basel). 2022 Aug 2;14(15):3769. doi: 10.3390/cancers14153769. PMID: 35954433; PMCID: PMC9367285. 
• Fosse V, Oldoni E, Gerardi C, Banzi R, Fratelli M, Bietrix F, Ussi A, Andreu AL, McCormack E, The Permit Group. Evaluating Translational Methods for Personalized Medicine-A Scoping Review. J Pers Med. 2022 Jul 19;12(7):1177. doi:10.3390/jpm12071177. PMID: 35887673; PMCID: PMC9324577.
• Poulose N, Forsythe N, Polonski A, Gregg G, Maguire S, Fuchs M, Minner S, Sauter G, McDade SS, Mills IG. VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in Prostate Cancer. Mol Cancer Res.
  2022 Jul 6;20(7):1047-1060. doi: 10.1158/1541-7786.MCR-21-0477. PMID: 35348747.
• Helland Å, Russnes HG, Fagereng GL, … and Smeland S (incl. Bjørge L, Gjertsen BT). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022 Jul 15;20(1):317. doi:
  10.1186/s12967-022-03518-0. Erratum for: J Transl Med. 2022 May 14;20(1):225. PMID: 35841045; PMCID: PMC9284821. 
• Clarsen B, Nylenna M, Klitkou ST, … and Knudsen AKS (incl. Norheim OF). Changes in life expectancy and disease burden in Norway, 1990-2019: an analysis of the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Jul;7(7):e593-e605. doi: 10.1016/S2468-2667(22)00092-5. PMID: 35779543; PMCID: PMC9253891. 
• Pianigiani G, Rocchio F, Peruzzi S, Andresen V, Bigerna B, Sorcini D, Capurro M, Gjertsen BT, Sportoletti P, Di Ianni M, Martelli MP, Brunetti L, Falini B. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. Leukemia. 2022 Jul;36(7):1931-1934. doi: 10.1038/s41375-022-01593-2. Epub 2022 May 14. PMID: 35568767; PMCID: PMC9252915.
• Shalabi S and LaBarge MA. Cellular and molecular mechanisms of breast cancer susceptibility. Clinical Sciences (London) 2022 Jul 15;136(13):1025-1043. doi: 10.1042/CS20211158. PMID: 35786748. 
• Barrett JJE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biol. 2022 Jun 29;23(1):142. doi: 10.1186/s13059-022-02704-z. Erratum for: Genome Biol. 2022 Feb 22;23(1):52. PMID: 35768851; PMCID: PMC9241178. 
• Kleinmanns K, Gullaksen SE, Bredholt G, Davidson B, Torkildsen CF, Grindheim S, Bjørge L, McCormack E. Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers (Basel). 2022 Jun 23;14(13):3092. doi: 10.3390/cancers14133092. PMID: 35804867; PMCID: PMC9265069. 
• Karunamuni RA, Huynh-Le MP, Fan CC, … and Seibert TM (incl. Mills IG). Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):229-237. doi: 10.1038/s41391-021-00403-7. Epub 2021 Jun 14. PMID: 34127801. 
• Lura N, Wagner-Larsen KS, Forsse D, Trovik J, Halle MK, Bertelsen BI, Salvesen Ø, Woie K, Krakstad C, Haldorsen IS. What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer? Insights Imaging. 2022 Jun 17;13(1):105. doi: 10.1186/s13244-022-01239-y. PMID: 35715582; PMCID: PMC9206052. 
• Madland K, Bjorge L, Småstuen MC, Dørum A, Vistad I. Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival? Int J Gynecol Cancer. 2022 Jun 9:ijgc2022-003361. doi: 10.1136/ijgc-2022-003361. Epub ahead of
  print. PMID: 35680138. 
• Steffens Reinhardt L, Groen K, Morten BC, Bourdon JC, Avery-Kiejda KA. Cytoplasmic p53β Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer. Int J Mol Sci. 2022 Jun 15;23(12):6670. doi: 10.3390/ijms23126670. PMID:
  35743117; PMCID: PMC9223648. 
• Bergholtz H, Lien T, Lingaas F, Sørlie T. Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. J Mammary Gland Biol Neoplasia. 2022 Jun;27(2):171-183. doi: 10.1007/s10911-022-09523-9. Epub 2022
  Aug 6. PMID: 35932380; PMCID: PMC9433360.
• Tranvåg EJ, Haaland ØA, Robberstad B, Norheim OF. Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions. JAMA Netw Open. 2022 Jun 1;5(6):e2219503. doi: 10.1001/jamanetworkopen.2022.19503. PMID: 35767256; PMCID: PMC9244608.
• Romaine A, Melleby AO, Alam J, Lobert VH, Lu N, Lockwood FE, Hasic A, Lunde IG, Sjaastad I, Stenmark H, Herum KM, Gullberg D, Christensen G. Integrin α11β1 and syndecan-4 dual receptor ablation attenuate cardiac hypertrophy in the pressure overloaded heart. Am J Physiol Heart Circ Physiol. 2022 Jun 1;322(6):H1057-H1071. doi: 10.1152/ajpheart.00635.2021. Epub 2022 May 6. PMID: 35522553. 
• Das R, Virlan MJR, Xenaki V, Kulasekara KK, Lukandu O, Neppelberg E, Vintermyr OK, Johannessen AC, Calenic B, Costea DE. Granulocyte macrophage-colony stimulating factor and keratinocyte growth factor control of early stages of differentiation of oral epithelium. Eur J Oral Sci. 2022 Jun;130(3):e12867. doi: 10.1111/eos.12867. Epub 2022 Apr 22. PMID: 35452148; PMCID: PMC9322408.
• Schiza A, Thurfjell V, Stenmark Tullberg A, Olofsson H, Lindberg A, Holmberg E, Bremer T, Micke P, Karlsson P, Wärnberg F, Strell C. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. Eur J Cancer. 2022 Jun;168:128-137. doi: 10.1016/j.ejca.2022.01.016. Epub 2022 Feb 27. PMID: 35236568. 
• Vanbraband J, Van Damme N, Bouche G, Silversmit G, De Geyndt A, de Jonge E, Jacomen G, Goffin F, Denys H, Amant F. Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT). BMC Cancer. 2022 Jun 1;22(1):600. doi: 10.1186/s12885-022-09671-5.PMID: 35650593. 
• Hua Y, Yuan X, Shen YH, Wang J, Azeem W, Yang S, Gade A, Lellahi SM, Øyan AM, Ke X, Zhang WD, Kalland KH. Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain. Front Pharmacol. 2022 May 27;13:836724. doi: 10.3389/fphar.2022.836724. PMID: 35712699; PMCID: PMC9196127.
• Perrone MG, Vitale P, Miciaccia M, Ferorelli S, Centonze A, Solidoro R, Munzone C, Bonaccorso C, Fortuna CG, Kleinmanns K, Bjørge L, Scilimati A. Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. Pharmaceuticals (Basel). 2022 May 26;15(6):668. doi: 10.3390/ph15060668. PMID: 35745587; PMCID: PMC9230671.
• Helland Å, Russnes HG, Fagereng GL, … and Smeland S. (incl. Bjørge L, Gjertsen BT). Improving public cancer care by implementing precision medicine in Norway: IMPRESSNorway. J Transl Med. 2022 May 14;20(1):225. doi: 10.1186/s12967-022-03432-5. Erratum in: J Transl Med. 2022 Jul 15;20(1):317. PMID: 35568909; PMCID: PMC9107632.
• Hodneland E, Kaliyugarasan S, Wagner-Larsen KS, Lura N, Andersen E, Bartsch H, Smit N, Halle MK, Krakstad C, Lundervold AS, Haldorsen IS. Fully Automatic WholeVolume Tumor Segmentation in Cervical Cancer. Cancers (Basel). 2022 May 11;14(10):2372. doi: 10.3390/cancers14102372. PMID: 35625977; PMCID: PMC9139985. 
• Taskén K, Russnes HEG, Aas E, … and Helland Å (incl. Bjørge L, Gjertsen BT, Hovland R). A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. PMID: 35513529.
• Dareng EO, Tyrer JP, Barnes DR, … and Pharoah PDP (incl. Bjorge L). Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 May;30(5):630-631. doi: 10.1038/s41431-022-01085-y. Erratum for: Eur J Hum Genet. 2022 Mar;30(3):349-362. PMID: 35314806; PMCID: PMC9090804.
• Engelsen AST, Lotsberg ML, Abou Khouzam R, Thiery JP, Lorens JB, Chouaib S, Terry S. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Front Immunol. 2022 Apr 27;13:869676. doi: 10.3389/fimmu.2022.869676. PMID: 35572601; PMCID: PMC9092944
• Lotsberg ML, Røsland GV, Rayford AJ, Dyrstad SE, Ekanger CT, Lu N, Frantz K, Stuhr LEB, Ditzel HJ, Thiery JP, Akslen LA, Lorens JB, Engelsen AST. Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. Front Oncol. 2022 Apr 22;12:818437. doi: 10.3389/fonc.2022.818437. PMID: 35530312; PMCID: PMC9076321.
• Huynh-Le MP, Karunamuni R, Fan CC, … and Seibert TM (incl. Mills IG). Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):755-761. doi:10.1038/s41391-022-00497-7. Epub 2022 Feb 12. PMID: 35152271.
• Wohlmuth C, Djedovic V, Kjaer SK, … and May T (incl. Thomsen LCV, Bjorge L). CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis. Cancers (Basel). 2022 Apr 13;14(8):1954. doi: 10.3390/cancers14081954. PMID: 35454861; PMCID: PMC9024456.
• Moshina N, Falk RS, Botteri E, Larsen M, Akslen LA, Cairns JA, Hofvind S. Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway. Qual Life Res. 2022 Apr;31(4):1057-1068. doi: 10.1007/s11136-021-03017-7. Epub 2021 Oct 26. PMID: 34698976; PMCID: PMC8547129. 
• Graham N, Pollard JW. An acid trip activates protumoral macrophages to promote hepatocellular carcinoma malignancy. J Clin Invest. 2022 Apr 1;132(7):e158562. doi:10.1172/JCI158562. PMID: 35362482. 
• Thy JE, Bhargava S, Larsen M, Akslen LA, Hofvind S. Early screening outcomes among non-immigrants and immigrants targeted by BreastScreen Norway, 2010-2019. Scand J Public Health. 2022 Mar 31:14034948221078701. doi:10.1177/14034948221078701. Epub ahead of print. PMID: 35361004.
• Rajthala S, Parajuli H, Dongre HN, Ljøkjel B, Hoven KM, Kvalheim A, Lybak S, Neppelberg E, Sapkota D, Johannessen AC, Costea DE. MicroRNA-138 Abates Fibroblast Motility with Effect on Invasion of Adjacent Cancer Cells. Front Oncol. 2022 Mar 17;12:833582. doi: 10.3389/fonc.2022.833582. PMID: 35371970; PMCID: PMC8968121. 
• Li H, Liu Z, Liu L, … and Brennen RA (incl. Rayford A, Gabra H, Lorens JB). AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. Cell Rep Med. 2022 Mar 15;3(3):100554.
  doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873; PMCID:PMC9040166.
• Rana N, Suliman S, Mohamed-Ahmed S, Gavasso S, Gjertsen BT, Mustafa K. Systemic and local innate immune responses to surgical co-transplantation of mesenchymal stromal cells and biphasic calcium phosphate for bone regeneration.
  Acta Biomater. 2022 Mar 15;141:440-453. doi: 10.1016/j. actbio.2021.12.027. Epub 2021 Dec 28. PMID: 34968726. 
• Ekanger CT, Zhou F, Bohan D, and Engelsen AST … (incl. Lotsberg ML, Ramnefjell M, Røsland GV, Lu N, Halvorsen T, Akslen LA, Lorens JB). Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. Front Cell Infect Microbiol. 2022 Mar 14;12:841447. doi: 10.3389/fcimb.2022.841447. PMID: 35360113; PMCID: PMC8964279. 
• Dareng EO, Tyrer JP, Barnes DR, … and Pharoah PDP (incl. Bjorge L, Thomsen LCV). Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 Mar;30(3):349-362. doi: 10.1038/s41431-021-00987-7. Epub
  2022 Jan 14. Erratum in: Eur J Hum Genet. 2022 Mar 22; PMID: 35027648; PMCID: PMC8904525.
• Fletcher CE, Deng L, Orafidiya F, … and Bevan CL (incl. Mills IG). A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Mol Cancer. 2022 Mar 22;21(1):82. doi:10.1186/s12943-022-01540-w. PMID: 35317841.
• Hofvind S, Knutsvik G, Holen ÅS, Tsuruda KM, Akslen LA. Detection and significance of small and low proliferation breast cancer. J Med Screen. 2022 Mar;29(1):32-37. doi: 10.1177/09691413211023970. Epub 2021 Jun 22. PMID: 34157879.
• Corti, L., Di Stefano, N., Bertolaso, M. (2022, June), Artificial Emotions: Toward a Human-Centric Ethics, International Journal of Social Robotics https://doi.org/10.1007/s12369-022-00890-1. 
• Barrett JE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biol. 2022 Feb 22;23(1):52. doi: 10.1186/s13059-022-02603-3. Erratum in: Genome Biol. 2022 Jun 29;23(1):142. PMID: 35189945; PMCID: PMC8862470. 
• Azeem W, Olsen JR, Hellem MR, Hua Y, Marvyin K, Ke X, Øyan AM, Kalland KH. Proteasome-Mediated Regulation of GATA2 Expression and Androgen Receptor Transcription in Benign Prostate Epithelial Cells. Biomedicines. 2022 Feb 17;10(2):473. doi: 10.3390/biomedicines10020473. PMID: 35203681; PMCID: PMC8962351. 
• Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjørge L, Zikan M, Cibula D, Widschwendter M. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun. 2022 Feb 1;13(1):448. doi: 10.1038/s41467-021-26615-y. PMID: 35105887; PMCID: PMC8807742. 
• Barrett JE, Herzog C, Jones A … and Widschwendter M (incl. Bjørge L). The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. 2022 Feb 1;13(1):449. doi:
  10.1038/s41467-021-27918-w. PMID: 35105882; PMCID: PMC8807602.
• Robinson, A, Burgess, M, Webb, S, Louwe, PA, Ouyang, Z, Skola, D, Han, C,Z, Batada, N.N, González-Huici, V., Cassetta, L., Glass, C.K., Jenkins, S.J., Pollard, J.W. Systemic influences of mammary cancers on monocytes in mice. Cancers (Basel). 2022 Feb 7;14(3):833. doi: 10.3390/cancers14030833. PMID: 35159100. 
• Bakunina K, Putter H, Versluis J, Koster EAS, van der Holt B, Manz MG, Breems DA, Gjertsen BT, Cloos J, Valk PJM, Passweg J, Pabst T, Ossenkoppele GJ, Löwenberg B, Cornelissen JJ, de Wreede LC. The added value of multistate modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. Cancer Med. 2022 Feb;11(3):630-640. doi: 10.1002/cam4.4392. Epub 2021 Dec 24. PMID: 34953042; PMCID: PMC8817075.
• Malani D, Kumar A, Brück O, … and Porkka K (incl. Hellesøy M, Gjertsen BT). Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290. CD-21-0410. Epub 2021 Nov 17. PMID: 34789538; PMCID: PMC9762335.
• Samson S, Northey JJ, Goga A, Flink CL, Weaver VM, and LaBarge MA. NCI’s publication conundrum: Reframing innovation to incentivize an equitable path for advocate representation. Translational Oncology 2022 Feb;16:101325. doi: 10.1016/j.tranon.2021.101325. Epub 2021 Dec 30. PMID: 34974281.
• Gaafar NM, Osman TA, Ahmed IA, Elsheikh M, Dongre H, Jacobsen MR, Mohamed NG, Fromreide S, Suleiman AM, Johannessen AC, Nginamau ES, Costea DE. Characterization of immune cell infiltrate in tumor stroma and epithelial compartments in oral squamous cell carcinomas of Sudanese patients. Clin Exp Dent Res. 2022 Feb;8(1):130-140. doi:10.1002/cre2.501. Epub 2021 Oct 9. PMID: 34626165; PMCID: PMC8874073.
• Gundersen ET, Førde JL, Tislevoll BS, Leitch C, Barratt G, Gjertsen BT, Herfindal L. Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation. Int J Pharm. 2022 Jan 25;612:121296. doi: 10.1016/j.ijpharm.2021.121296. Epub 2021 Nov 15. PMID: 34793932.
• Liu XZ, Rulina A, Choi MH, Pedersen L, Lepland J, Takle ST, Madeleine N, Peters SD, Wogsland CE, Grøndal SM, Lorens JB, Goodarzi H, Lønning PE, Knappskog S, Molven A, Halberg N. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. Nat Commun. 2022 Jan 10;13(1):69. doi: 10.1038/s41467-021-27734-2. PMID: 35013251; PMCID: PMC8748947. 
• Dybvik JA, Fasmer KE, Ytre-Hauge S, Husby JHA, Salvesen ØO, Stefansson IM, Krakstad C, Trovik J, Haldorsen IS. MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. Insights Imaging. 2022 Jan 8;13(1):1. doi: 10.1186/s13244-021-01133-z. PMID: 35000020; PMCID: PMC8742796.
• Kang J, Cairns J. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy. BMJ Open. 2022 Jan 6;12(1):e055985. doi: 10.1136/bmjopen-2021-055985. PMID:
  34992121; PMCID: PMC8739419.
• Shanbhag S, Kampleitner C, Mohamed-Ahmed S, Yassin MA, Dongre H, Costea DE, Tangl S, Hassan MN, Stavropoulos A, Bolstad AI, Suliman S, Mustafa K. Corrigendum: Ectopic Bone Tissue Engineering in Mice Using Human Gingiva or Bone Marrow-Derived Stromal/Progenitor Cells in Scaffold-Hydrogel Constructs. Front Bioeng Biotechnol. 2022 Jan 4;9:831669. doi: 10.3389/fbioe.2021.831669. Erratum for: Front Bioeng Biotechnol. 2021 Nov 30;9:783468. PMID: 35059391; PMCID: PMC8764244.
• Harryvan TJ, Hawinkels LJAC; mini-tumor workgroup; Östman A, Ten Dijke P, Strell C, Hornsveld M. A Novel Pancreatic Cancer Mini-tumor Model to Study Desmoplasia and Myofibroblastic Cancer-Associated Fibroblast Differentiation. Gastro Hep Adv. 2022;1(4):678-681. doi:10.1016/j.gastha.2022.04.019. PMID: 35937541; PMCID: PMC9340885.
• Popa M, Fosse V, Kleinmanns K, Bjørge L, McCormack E. Xenograft Models of Ovarian Cancer for Therapy Evaluation. Methods Mol Biol. 2022;2424:275-293. doi: 10.1007/978-1-0716-1956-8_18. PMID: 34918301. 
• Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. Int J Cancer. 2022 Jan 1;150(1):100-111. doi: 10.1002/ijc.33768. Epub 2021 Sep 9. PMID: 34449877. 
• Forsse D, Barbero ML, Werner HMJ, Woie K, Nordskar N, Berge Nilsen E, Ellstrøm Engh M, Vistad I, Rege A, Sævik-Lode M, Andreasen S, Haldorsen IS, Trovik J, Krakstad C. Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. Am J Obstet Gynecol. 2022 Jan;226(1):90.e1-90.e20. doi: 10.1016/j.ajog.2021.08.011. Epub 2021 Aug 13. PMID: 34400137. 
• Zhang X, Groen K, Morten BC, Steffens Reinhardt L, Campbell HG, Braithwaite AW, Bourdon JC, Avery-Kiejda KA. Effect of p53 and its N-terminally truncated isoform, Δ40p53, on breast cancer migration and invasion. Mol Oncol. 2022 Jan;16(2):447-465. doi: 10.1002/1878-0261.13118. Epub 2021 Nov 23. PMID: 34657382; PMCID: PMC8763661.
• Watnick, RS. The Role of the Tumor Microenvironment in Regulating Angiogenesis. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 3-15. 
• Akslen, LA. Tissue-Based Biomarkers of Tumor-Vascular Interactions. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 17-30. 
• Milosevic M, Edelmann RJ, Fosse JH, Östman A, Akslen LA. Molecular Phenotypes of Endothelial Cells in Malignant Tumors. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 31-52.
• Zeltz C, Navab R, Lu N, Kusche-Gullberg M, Tsao MS, Gullberg D. Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support? In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 63-89.
• Dongre H, Costea DE. Tumor-Fibroblast Interactions in Carcinomas. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 109-124.
• Strell C, Östman A. Stromal PDGF Receptors; Impact on Prognosis and Response to Treatment. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 125-138.
• Brekken RA, Wnuk-Lipinska K. Drivers of EMT and Immune Evasion. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 183-194.
• Vethe H, Bjørnstad OV, Carrasco M, Akslen LA. Neurogenesis in the Tumor Microenvironment. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 283-293.
• Lotsberg ML, Davidsen KT, Peters S, Haaland GS, Rayford A, Lorens JB, Engelsen AST. The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 307-327.
• Kleinmanns K, Gjerde CH, Langer A, Fosse V, de Jalón EG, Leitch C, Popa M, Gelebart P, McCormack E. Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 329-344.
• Wik E, Ingebriktsen LM, Akslen LA. Gene Expression Signatures of the Tumor Microenvironment: Relation to Tumor Phenotypes and Progress in Breast Cancer. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 401-424.
• Jokela TA, Carlson EG, LaBarge MA. The Influence of Tissue Architecture on Drug Response: Anticancer Drug Development in High-Dimensional Combinatorial Microenvironment Platforms. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 441-452.
• Azeem W, Hua Y, Kalland KH, Ke X, Olsen JR, Øyan AM, Qu Y. Models of Tumor Progression in Prostate Cancer. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 453-465.
• Magnussen AL, Mills IG. Prostate Cancer Biomarkers: The Old and the New. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 467-482. 
• Ramnefjell M, Akslen LA. Tumor-Vascular Interactions in Non-Small Cell Lung Cancer. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 497-508. 
• Dillekås D, Schuster C, Davidsen KT, Straume O. The Role of the Microenvironment in Tumor Promoting Stress Responses. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 519-536. 
• Jebsen NL, Ktoridou-Valen I, Gjertsen BT. Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 549-562. 
• Sim WJ, Lee KC, Thiery JP. Cancer Biomarkers: A Long and Tortuous Journey. In: Akslen LA, Watnick RS (eds), Biomarkers of the Tumor Microenvironment, 2022, Springer, p. 563-580. 
• Dillekås HE. “Reconstruction of Trouble”. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer, p. 61-68.
• Gissum KR. Lost in Translation. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer, p. 69-95.
• Bremer A, Wik E, Akslen LA. HER2 Revisited: Reflections on the Future of Cancer Biomarker Research. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer,
  p. 97-119.
• Strand R, Chu D. Crossing the Styx: If Precision Medicine Were to Become Exact Science. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer, p. 133-154.
• Lotsberg ML, Peters SA. Publication Bias in Precision Oncology and Cancer Biomarker Research; Challenges and Possible Implications. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer, p. 155-174.
• Cairns, JA. Assessing the Cost-Effectiveness of Molecular Targeted Therapies and Immune Checkpoint Inhibitors. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology,
  2022, Springer, p. 175-185.
• Kang J. Real-World Data in Health Technology Assessment: Do We Know It Well Enough? In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer, p. 187-203
• Tranvåg EJ, Strand R. Rationing of Personalised Cancer Drugs: Rethinking the Co-production of Evidence and Priority Setting Practices. In: Bremer A., Strand R. (eds) Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and
  Technology, 2022, Springer, p. 235-250.
• Strand R, Engen C. Filled with Desire, Perceive Molecules. In: Bremer A, Strand R (eds), Precision Oncology and Cancer Biomarkers. Human Perspectives in Health Sciences and Technology, 2022, Springer, p. 251-267.
• Bertolaso M, Velázquez H. The Epistemology of Life - Understanding living beings according to a relational ontology. In: Wuppuluri S, Stewart I (eds) From Electrons to Elephants and Elections: Exploring the Role of Content and Context, 2022, Springer, p. 719-741.
• Bertolaso M. Complexity and Management: Epistemic Insights from Life Science. In: Neesham C, Reihlen M, Schoeneborn D (eds) Handbook of Philosophy of Management, 2022, Springer, p. 333-355.
• Bertolaso M, Capone L, Rodrìguez-Llesma C (eds). Digital Humanism - A Human-Centric Approach to Digital Technologies, Palgrave – Springer, 2022.

2020

2019

2018

2017

2016

2015

2014

2013